Universal Health Services, Inc.

Universal Health Services, Inc. (UHS) Market Cap

Universal Health Services, Inc. has a market capitalization of โ€”.

No quote data available.

CEO: Marc D. Miller

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1981-07-09

Website: https://uhs.com

Universal Health Services, Inc. (UHS) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Universal Health Services, Inc. (UHS), operating through its various divisions, is a healthcare entity that both owns and manages a network of acute care hospitals, along with outpatient and specialized behavioral health treatment centers. Its business operations are strategically bifurcated into two main segments: Acute Care Hospital Services and Behavioral Health Care Services. The hospitals under its management provide a comprehensive spectrum of medical provisions, encompassing general and specialty surgical interventions, internal medicine, obstetrics, urgent and emergency department services, diagnostic imaging (radiology), cancer therapy (oncology), advanced diagnostic procedures, cardiac care, pediatric medicine, pharmaceutical services, and mental health support. As of a reported date of February 24, 2022, the company's significant presence included the ownership or operation of 363 inpatient facilities, complemented by 40 outpatient and other specialized sites. These facilities are distributed across 39 U.S. states, the District of Columbia, the United Kingdom, and Puerto Rico. Beyond direct patient care, UHS also extends into commercial health insurance provision and offers a variety of crucial management support functions. These include centralized procurement, information technology infrastructure, financial oversight and control mechanisms, strategic facilities planning, physician talent acquisition, administrative staff management, marketing initiatives, and public relations efforts. Universal Health Services, Inc. was established in 1978 and maintains its principal executive offices in King of Prussia, Pennsylvania.

Analyst Sentiment

62%
Buy

From 21 Active Polls

1Y Forecast: $193.78

โ–ฒ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$166

Median

$190

High Bound

$290

Average

$194

Price & Moving Averages

Loading chart...

๐ŸŽฏ Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$193.78
โ–ฒ +15.04% Upside
Low Target
$166.00
-1% Risk
Median Target
$190.00
13% Mid
High Target
$290.00
72% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

๐Ÿ“˜ Full Research Report

โ„น๏ธ

AI-Generated Research: This report is for informational purposes only.

๐Ÿ“˜ UNIVERSAL HEALTH SERVICES INC CLAS (UHS) โ€” Investment Overview

๐Ÿงฉ Business Model Overview

Universal Health Services operates a network of inpatient facilities and related services in the U.S., with a meaningful emphasis on behavioral health (including acute psychiatric and specialty/substance-use services) alongside acute-care hospital operations. The value chain is built around (1) acquiring and operating licensed healthcare facilities, (2) staffing and operating them to deliver clinically appropriate care, (3) managing patient flow through physician relationships and referral channels, and (4) billing payers under government programs and commercial insurance arrangements. Patient volumes and length-of-stay drive utilization, while payer mix and reimbursement terms drive net revenue realization.

A key source of customer stickiness comes from the combination of licensed capacity, established referral patterns, and discharge planning pathways. While patients can choose providers, referral sources and payer/provider administrative infrastructure reduce churn, and rebuilding comparable local capacity is slow due to staffing, licensing, and operational ramp requirements.

๐Ÿ’ฐ Revenue Streams & Monetisation Model

Revenue is primarily generated from facility-based clinical care, typically recognized through a mix of reimbursement structures that include per diem and other case/service-based models, with payers spanning government programs (Medicare and Medicaid) and commercial insurers. Monetisation is driven by:

  • Inpatient services: Core volume engine; profitability depends on occupancy, acuity, coding/documentation, and clinical outcomes that support appropriate reimbursement.
  • Behavioral health and specialty services: Revenue tends to be sensitive to demand trends for mental health and substance-use treatment, as well as regulatory and payer coverage policies.
  • Outpatient and ancillary services (where present): Provides diversification and can support smoother utilization across the care continuum.

Margin drivers generally include labor efficiency (nursing and clinical staffing models), pharmacy and supply utilization, denial management, and the ability to keep growth aligned with operating capacity. Because healthcare is heavily compliance- and documentation-dependent, net revenue realization is strongly influenced by coding accuracy, documentation integrity, and payer contracting terms.

๐Ÿง  Competitive Advantages & Market Positioning

UHSโ€™s moat is anchored less in branding and more in hard-to-replicate operating and regulatory capabilities that support licensed capacity and reliable reimbursement. The competitive advantages are best characterized as regulatory/operational barriers to entry plus integrated referral and care delivery ecosystems.

  • High barriers to entry (regulatory + accreditation + licensing): Building and scaling comparable hospital capacity requires state/federal licensing, regulatory compliance, accreditation, and substantial clinical workforce availability. This raises competitor entry costs and slows replacement of capacity in a given geography.
  • Operational expertise and reimbursement execution: Complex payers and documentation requirements create a performance gap between operators; robust denial management, coding discipline, and payer contract execution can materially affect net revenue.
  • Integrated ecosystems (referral pathways and discharge planning): Behavioral health models rely on referral sources (e.g., clinicians, managed care networks, community partners) and effective transitions of care. This dynamic supports patient flow durability and reduces effective churn versus a purely transactional model.

Competitive benchmarking: UHSโ€™s closest public peers include Acadia Healthcare (behavioral health focus), Tenet Healthcare (acute-care hospital operator with different facility mix), and HCA Healthcare (large acute-care network with scale and contracting sophistication). Compared with these rivals, UHSโ€™s positioning emphasizes behavioral/specialty capacity and the operational cadence of specialty care delivery, whereas larger acute-care peers typically benefit more from scale across broad hospital services. Competitors can replicate facilities over time, but the combination of licensing, staffing, and reimbursement execution remains a sustained execution advantage.

๐Ÿš€ Multi-Year Growth Drivers

Over a 5โ€“10 year horizon, growth is supported by secular demand and capacity rebalancing rather than purely cyclical healthcare spending:

  • Rising demand for mental health and substance-use treatment: Policy focus and improved clinical recognition support steady addressability for behavioral health providers, including inpatient and specialty levels of care.
  • Capacity constraints and replacement cycles: Healthcare facilities often face long lead times for new capacity due to licensing, workforce, and capital requirements, creating pricing and utilization support for well-run operators.
  • Site and service expansion within existing platforms: Operators can add capacity, refine service lines, and improve throughput using existing compliance and operational infrastructure.
  • Care continuum integration: Stronger linkage between inpatient stabilization, outpatient follow-up, and community-based transitions can support better clinical outcomes and improve payer confidence, supporting volume durability.

TAM expansion is primarily driven by treatment coverage, care delivery models, and the healthcare systemโ€™s need to absorb behavioral health demand into licensed care settings.

โš  Risk Factors to Monitor

  • Reimbursement and payer policy risk: Changes in Medicare/Medicaid reimbursement methodology, commercial payer contracting, and behavioral health coverage rules can affect net revenue realization.
  • Labor availability and wage inflation: Healthcare operations are structurally sensitive to staffing supply, wage pressure, and agency utilization. Sustained labor cost increases can compress margins.
  • Regulatory, compliance, and oversight: Behavioral health and inpatient care models face heightened scrutiny related to patient safety, quality measures, and documentation. Adverse findings can increase cost and constrain growth.
  • Capital intensity and facility performance: Expansion requires meaningful capital deployment and operating ramp management; underperforming facilities can dilute consolidated returns.
  • Denials, coding, and reimbursement execution: Errors in documentation or contracting disputes can reduce cash receipts and raise earnings volatility.

๐Ÿ“Š Valuation & Market View

Healthcare operators like UHS are typically valued through earnings power rather than asset-only metrics. Market focus often centers on:

  • EV/EBITDA and operating margin trajectory: Investors underwrite sustained profitability from utilization, net revenue realization, and cost discipline.
  • Earnings quality and cash conversion: Resolution of denials, working capital dynamics, and payer settlement patterns can influence perceived durability of earnings.
  • Facility-level performance indicators: Trends in occupancy/utilization, labor intensity, and documentation/coding performance can move sentiment.

Key valuation sensitivities typically include labor cost outlook, reimbursement environment, and visibility into facility-level throughput improvements.

๐Ÿ” Investment Takeaway

UHSโ€™s long-term investment case rests on durable barriers to entry in licensed healthcare capacity, reinforced by execution capabilities in clinical operations and reimbursement discipline. The companyโ€™s emphasis on behavioral health and specialty care provides a defensible platform with structural demand support and an ecosystem advantage tied to referral pathways and continuity of careโ€”advantages that are difficult to replicate quickly for new entrants or under-optimized operators.


โš  AI-generated โ€” informational only. Validate using filings before investing.

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"UHS reported Q2โ€™26 revenue of $4.64B and net income of $358M (EPS $5.87). YoY (vs Q2โ€™25) revenue rose to 4.64B from 4.28B (+8.2%), and net income increased to $358M from $353M (+1.5%), indicating earnings growth lagged revenue. QoQ (vs Q1โ€™26) revenue grew (+3.2%, $4.50B to $4.64B) while net income rose modestly (+2.8%, $349M to $358M). Profitability was mixed across the quarter-to-quarter window: reported net margin was broadly stable around ~7.7โ€“8.0% (Q2โ€™26 net margin 7.73% vs 7.76% in Q1โ€™26 and 8.25% in Q2โ€™25), suggesting no major margin expansion. Operating margin remained ~11% (Q2โ€™26 11.14%). Cash flow quality looks solid for a healthcare services operator: operating cash flow was $443M and free cash flow $216M in Q2โ€™26. Shareholder returns remain supported primarily by capital returnโ€”UHS repurchased $321M of stock in the quarter and paid dividends of $11.8M, consistent with a low payout ratio (~3%). On leverage/balance sheet, the company continues to carry substantial debt (net debt ~$5.12B) but equity was stable at ~$7.66B. Price momentum is moderate (1y_change +5.0%), which limits the total-return uplift versus a >20% momentum name."

Revenue Growth

Good

QoQ revenue +3.2% ($4.50B to $4.64B) and YoY revenue +8.2% ($4.28B to $4.64B), showing solid top-line momentum.

Profitability

Neutral

Net income grew slower than revenue: YoY net income +1.5%, with net margin slightly lower vs Q2โ€™25 (7.73% vs 8.25%) and roughly flat QoQ (7.73% vs 7.76%). No clear margin expansion.

Cash Flow Quality

Positive

Q2โ€™26 operating cash flow was $443M and free cash flow $216M, supporting ongoing shareholder returns. Dividends were modest (~$11.8M) with low payout ratio (~3%).

Leverage & Balance Sheet

Positive

Balance sheet is leveraged (net debt ~$5.12B) but equity is stable (~$7.66B). Debt levels remain sizable though interest coverage is strong (Q2โ€™26 ~12.9x).

Shareholder Returns

Positive

Capital return is active (share repurchases ~$321M in Q2โ€™26; dividends ~$12M). Total-shareholder momentum is moderate: 1y price change +5.0% (no >20% uplift).

Analyst Sentiment & Valuation

Fair

Market price (~$182.41) sits below the consensus target (~$193.78), implying limited upside versus the targets (high 290/low 166 reflect wide dispersion).

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

UHS reported Q2 2026 adjusted EPS of $5.98 (+12% YoY) and adjusted EBITDA less NCI of $678M (+5% YoY), but results were mixed versus internal expectations once excluding the ~$100M out-of-period Florida DPP benefit. Management cited a ~$63M shortfall driven by higher professional & general liability reserves (~$28M), San Antonio behavioral facility impacts (~$20M), and slower Cedar Hill de novo ramp (~$15M). Operationally, acute care showed resilient demand with same-facility adjusted admissions +2.9% and ED visits +4%, despite surgeries -0.8% and sector-wide outpatient displacement pressure. Behavioral health net revenue grew +7.4% with patient-day growth +1.4% and strong EBITDA. Guidance was fine-tuned: 2026 adjusted EBITDA less NCI lowered by ~$50M at midpoint to $2.61Bโ€“$2.72B, while volume ranges for admissions/patient days were reduced ~50โ€“100 bps midpoints. Key swing factors in 2H include acute bed ramps, Cedar Hill timing, and Talkspace outpatient acceleration (mid-August close).

AI IconGrowth Catalysts

  • Added 177 licensed acute care beds across 3 hospitals in Q2 2026 (+2.5% same-facility bed capacity), supporting demand capture and ongoing ramp-throughout 2H
  • Alan B. Miller Medical Center in Palm Beach Gardens opened in May; achieved Joint Commission accreditation in July (de novo growth runway and demand reception)
  • Behavioral health: integration planning progressing for pending Talkspace acquisition expected to close mid-August, targeting acceleration in outpatient via virtual services
  • Cedar Hill Regional Medical Center (Washington, D.C.) benefit expected to improve through the year as it continues ramping and moves toward breakeven timing
  • California nurse staffing ratio requirements (effective June 1): management indicated success in hiring/training supports maintaining the contemplated $35M impact in 2026

Business Development

  • Talkspace acquisition: expected close mid-August 2026; framed as creating an end-to-end behavioral health continuum including virtual outpatient
  • Florida DPP program: 2025 portion approved and recognized in Q2; management highlighted Q2 $100M out-of-period benefit not contemplated in original outlook
  • California DPP program: โ€œrecent approvalโ€ referenced as already recorded; stated to be not material
  • Texas behavioral hospital recertification process underway (Laurel Ridge Hospital): stopped receiving reimbursement end of April; recertification anticipated in 2027

AI IconFinancial Highlights

  • Adjusted EPS: $5.98 (+12% YoY)
  • Q2 adjusted EBITDA less NCI: $678M (+5% YoY); excluding $100M out-of-period Florida DPP benefit, Q2 adjusted EBITDA less NCI fell short of internal expectations by ~ $63M
  • Outperformance/shortfall drivers (approx. $63M total): $28M higher professional & general liability reserves; ~$20M impact tied to San Antonio behavioral facility; ~$15M due to slower ramp-up at Cedar Hill de novo facility in Washington, D.C.
  • Volume-to-guidance adjustment: management fine-tuned full-year acute care adjusted admissions guidance to 1.5%โ€“2.5% (midpoint ~50 bps lower than prior range) and behavioral health adjusted patient days to 1.0%โ€“2.0% (midpoint ~100 bps lower than prior range)
  • Acute care same-facility: adjusted admissions +2.9%; ED visits +4% while surgeries -0.8% vs Q2โ€™25; net revenue +8.2% (+5.9% excluding health plan impact); EBITDA +8.2% (+6.3% excluding out-of-period supplemental benefits)
  • Behavioral health same-facility: net revenue +7.4% driven by patient days +1.4% and revenue per adjusted patient day +6.1%; EBITDA +9.0% (+5.7% excluding out-of-period supplemental benefits)
  • Exchange trends: impact estimated at ~$20M in Q2 (in line with expectations); exchange volumes -15% YoY with self-pay offset; updated full-year pretax impact: upper half of prior guidance (~$85M)

AI IconCapital Funding

  • Share repurchase accelerated in Q2: $320M total cost vs $127M in Q1 2026
  • Q2 shares repurchased: 1.89 million
  • June 30, 2026: $978M remaining authorization under stock buyback program; management intends to remain active throughout 2026
  • Balance sheet (Jun 30, 2026): cash $139M; total debt $4.85B; net leverage 1.8x; revolver additional borrowing capacity $1.27B

AI IconStrategy & Ops

  • Capacity expansion: new licensed beds and de novo ramp to extend footprint in acute and behavioral markets with convenient access points aligned with physician stakeholders
  • Expense management: labor and supply managed; supply expense per admission -2.5% YoY; contract labor 2.5% of acute segment revenue, down 20 bps YoY
  • Regulatory/actuarial impacts: higher professional & general liability reserves increased quarterly expense going forward via semiannual third-party actuarial review
  • De novo operations: Palm Beach Gardens startup losses in-line; Cedar Hill ramp slower than expected with continued improvement toward breakeven assumptions
  • Outpatient displacement mitigation: continued investment in ASCs and ambulatory OR capacity plus advanced imaging/robotics to support procedural volumes despite outpatient shift

AI IconMarket Outlook

  • Updated 2026 guidance (midpoint): ~7% revenue growth, ~3% EBITDA less NCI growth, ~6% EPS growth
  • Adjusted EBITDA less NCI updated range: $2.61Bโ€“$2.72B (midpoint $2.665B); decreased by ~$50M vs prior outlook midpoint
  • Full-year Medicaid supplemental funding benefit: now ~$1.5B (increase ~$150M vs prior), including: $100M Florida recognized in Q2; ~$25M Texas ATLIS expected in Q3
  • Professional & general liability expense: increased by ~$50M full-year (28M recognized in Q2; remainder split through 2H)
  • Texas behavioral facility recertification: no government/managed care reimbursement expected until recertification in 2027; guidance includes $50M impact total (loss of ~$30M earnings + ~$20M operating losses assumed for full-year)

AI IconRisks & Headwinds

  • Professional & general liability reserve build: Q2 added ~$28M; guidance increased P&G liability expense estimate by ~$50M for 2026 due to higher claim severity (industry-wide; difficult to predict future deceleration)
  • Texas behavioral hospital recertification risk: reimbursement stopped end of April; operating losses expected $5Mโ€“$10M per quarter for remainder of 2026; excluded from same-facility performance
  • Cedar Hill de novo ramp: slower-than-expected pace reduced tailwind assumption (guidance tailwind reduced from $50M to ~$20M with Cedar Hill breakeven pushed to Q4)
  • Exchange volume pressure: exchange volumes down ~15% YoY; management expects full-year pretax exchange impact in the upper half of original range (~$85M), though first-half decline was below original 25%+ assumption
  • Elective/outpatient shift: management attributed acute volume softness vs midpoint to elective/outpatient procedures moving to alternate-site settings (ASCs, freestanding imaging), consistent with CMS/sectoral shift

Q&A: Analyst Interest

  • Acute care volume drivers: Management explained the modest acute admission growth deceleration as a reflection of first-half performance and an ongoing shift of elective/outpatient procedures to alternate sites (ASCs, freestanding imaging). They emphasized surgical rebound in Q2 and adjusted guidance by lowering the back-half admission midpoint.
  • Back-half EBITDA acceleration drivers: Management connected the implied back-half EBITDA acceleration to (1) continuing ramp of three acute bed expansion projects begun in Q2 (177 beds), (2) Cedar Hillโ€™s improved trajectory toward breakeven expectations, (3) moderation in behavioral labor/headcount growth, and (4) easier 2H comparisons including Nevada seasonality.
  • Malpractice reserve visibility: Management stated third-party actuaries set reserve amounts and updates occur through twice-yearly actuarial reviews. They attributed increases to broader claim severity inflation across acute and behavioral care, said UHS-specific control is limited versus tort reform/litigation severity, and noted ongoing industry lobbying with unpredictable outcomes.

Sentiment: MIXED

Note: This summary was synthesized by AI from the UHS Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
ยฉ 2026 Stock Market Info โ€” Universal Health Services, Inc. (UHS) Financial Profile